Delstrigo

Delstrigo is a fixed-dose combination antiretroviral medication used for the treatment of HIV-1 infection. It contains three active components in a single tablet: doravirine (an NNRTI), lamivudine (3TC), and tenofovir disoproxil fumarate (TDF). The tablet is taken once daily, with or without food.

Doravirine works by inhibiting HIV-1 reverse transcriptase, an enzyme the virus needs to replicate. Lamivudine and tenofovir disoproxil fumarate are nucleoside/nucleotide reverse transcriptase inhibitors that also disrupt viral replication. Together, the three drugs form a complete regimen intended to suppress HIV-1 RNA to undetectable levels when used as prescribed.

Indications and usage guidelines specify that Delstrigo is a complete regimen for the treatment of HIV-1 infection in adults and certain pediatric patients, suitable for initial therapy in treatment-naive individuals and as a switch strategy for virologically suppressed patients on stable antiretroviral regimens. Patients should be assessed for resistance to any component before starting therapy. It is not recommended for individuals with known resistance to doravirine, lamivudine, or tenofovir disoproxil fumarate.

Safety and side effects: common adverse effects include dizziness, nausea, fatigue, vomiting, diarrhea, and headache. Potential serious risks include renal toxicity and effects on bone mineral density due to the tenofovir component, as well as lactic acidosis or hepatotoxicity in rare cases. Drug interactions are important; strong CYP450 inducers or inhibitors can affect doravirine levels, and concomitant use with certain medications (such as rifampin) is typically avoided. Regular monitoring of kidney function, liver enzymes, and HIV RNA is advised during treatment. Delstrigo was approved by the U.S. FDA in 2020 and is available in other regions under similar indications.